 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Aug 31, 2024 |
| Title |
Adipose-Tumor Crosstalk contributes to CXCL5 Mediated Immune Evasion in PDAC |
| Organism |
Homo sapiens |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
BACKGROUND: CXCR1/2 inhibitors are being implemented with immunotherapies in PDAC clinical trials. CXCL ligands are a family of cytokines responsible for stimulating these receptors; while typically secreted by activated immune cells, fibroblasts, and even adipocytes, they are also secreted by immune-evasive cancer cells. CXCL ligand release is known to occur in response to inflammatory stimuli, whether pathogenic (bacterial) or endogenous (obesity). Obesity has been linked to poor patient outcome and altered anti-tumor immunity in pancreatic cancer. Importantly, adipose-derived cytokines and chemokines have been implicated as potential drivers of tumor cell immune evasion; cumulatively these findings suggest that targeting CXC ligands may be beneficial in the context of obesity.
METHODS: RNA-sequencing of human PDAC cell lines was used to assess differential influences of adipose conditioned media on the cancer cell transcriptome. In addition, the adipose-induced secretome of PDAC cells was validated with ELISA for induced CXCL5 secretion. Human tissue data from CPTAC was used to correlate IL-1β and TNF expression with both CXCL5 mRNA and protein levels. CRISPR-Cas9 was used to knock out CXCL5 from a murine PDAC cell line in order to assess orthotopic tumor studies in syngeneic, diet-induced obese mice. Flow cytometry was used to compare the immune profiles between tumors. Mice were monitored for differences in tumor size at endpoint in combination with Anti-PD-1 immune checkpoint blockade therapy.
RESULTS: Human adipose conditioned media (hAT-CM) stimulates CXCL5 secretion from PDAC cells via either IL-1β or TNF; neutralization of both is required to significantly block release of CXCL5 from tumor cells. Ablation of CXCL5 from tumors promoted an enriched immune phenotype with an unanticipatedly increased number of exhausted CD8 T cells. Application of anti-PD-1 treatment to control tumors failed to alter tumor growth, yet treatment of CXCL5 deficient tumors showed response by significantly diminished tumor mass.
CONCLUSIONS: In summary, our findings show that both TNF and IL-1β can stimulate CXCL5 release from PDAC cells in vitro, which correlates with expression in patient data. CXCL5 depletion in vivo alone is sufficient to promote T cell infiltration into tumors, increasing efficacy of checkpoint blockade inhibition and alleviating tumor burden.
|
| |
|
| Overall design |
Human peri-pancreatic adipose was collected from pancreatic cancer patients during surgical resection. Conditioned media was made from the tissue, and used to stimulate human cell lines in tissue culture. Cells treated with serum free media or conditioned media were analyzed by RNA sequencing to assess factors from adipose tissue altering pancreatic cancer transcriptional profiles.
|
| |
|
| Contributor(s) |
McKinnon WR, Ambrose J, Jack J, Eades A, Bye B, Ruckert M, Messaggio F, Olou A, Chalise P, Pei D, VanSaun M |
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| |
| Submission date |
Aug 13, 2024 |
| Last update date |
Aug 31, 2024 |
| Contact name |
Michael VanSaun |
| E-mail(s) |
mvansaun@kumc.edu
|
| Organization name |
The University of Kansas Medical Center
|
| Street address |
3901 Rainbow Blvd
|
| City |
Kansas City |
| State/province |
KS |
| ZIP/Postal code |
66160 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL24676 |
Illumina NovaSeq 6000 (Homo sapiens) |
|
| Samples (30)
|
|
| Relations |
| BioProject |
PRJNA1147698 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE274713_Normalized_counts_Supplemental_Table.xlsx |
4.4 Mb |
(ftp)(http) |
XLSX |
SRA Run Selector |
| Raw data are available in SRA |
|
|
|
|
 |
Less...
More...